Intensive Medicines Monitoring Study of Toripalimab Monoclonal Injection (Tuoyi) .
A Prospective, Single-arm, Multicenter, Non-interventional Real-world Study of Toripalimab Injection in the Treatment of Malignant Tumors in Chinese Population.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: jun guo, MD PhD
- Phone Number: 8610-88121122
- Email: guoj307@126.com
Study Locations
-
-
-
Beijing, China
- Cancer Hospital Chinese Academy of Medical Science
-
Changchun, China
- The first affiliated Hospital of Jinlin Universtiy
-
Changsha, China
- Xiangya Hospital Central South University
-
Changsha, China
- Hunan Cancer Hospital
-
Chongqing, China
- Chongqing Haijiya Cancer Hospital
-
Fuzhou, China
- Fujian Province Cancer Hospital
-
Hangzhou, China
- Zhejiang Cancer Hospital
-
Harbin, China
- Harbin Medical University Cancer Hospital
-
Jinan, China
- Qilu Hospital of Shandong University
-
Jinan, China
- Shandong province cancer hospital
-
Nanjing, China
- Affiliated Cancer Hospital of Guangxi Medical University
-
Nanjing, China
- Najing Drum Tower Hospital
-
Shanghai, China
- Fudan University Shanghai Cancer Center
-
Shanxi, China
- Shanxi Bethune Hopital
-
Shijiazhuang, China
- The fouth Hospital of Hebei Medical University
-
Suzhou, China
- The Second affiliated Hospital of Suzhou Universtiy
-
Tianjin, China
- Tianjin Medical University Cancer Institute & Hospital
-
Wuhan, China
- Hubei Cancer Hospital
-
Wuhan, China
- Tongji Medical College of Huazhong University of Science & Technology
-
Wuhan, China
- Wuhan Union Hospital
-
Xiamen, China
- The first affiliated Hospital of Xiamen Universtiy
-
Yinchuan, China
- Yinchuan Lingke Internet Hosipital
-
Zhanjiang, China
- Affiliated Hopital of Guangdong Medical University
-
Zhengzhou, China
- Henan Cancer Hospital
-
-
Beijing
-
Beijing, Beijing, China, 100142
- Beijing Cancer Hospital
-
Contact:
- jun guo
- Phone Number: 8610-88121122
- Email: guoj307@126.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with approved indications of Toripalimab injection;
- Patients treated with Toripalimab injection;
- Patients who agreed to participate in this study and signed an informed consent form.
Exclusion Criteria:
- Refused to participate or refused to cooperate with the procedure;
- Those who participated in the intervention study of other unapproved drugs / therapies and less than 5 half-lives after the last use of the study drugs.
Study Plan
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Toripalimab injection
Use of Toripalimab injection in the real world
|
240 mg/6 mL/vial.
The recommended dose of Toripalima is 3 mg/kg, intravenous infusion every 2 weeks until disease progression or intolerable toxicity.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The incidence of all ADR.
Time Frame: 3 years
|
the incidence of all ADR: the number and percentage of patients with ADR, and the number of ADR events will be summarized according to the International Medical Dictionary (MedDRA) preferred terminology and adverse events General terminology Standard (NCI CTCAE5.0
Chinese version).
Any ADR collected during the study will be included in the ADR summary.
|
3 years
|
|
known ADR.
Time Frame: 3 years
|
The incidence of known adverse reactions ((ADR)).
|
3 years
|
|
The occurrence of new adverse reactions ((ADR)
Time Frame: 3 years
|
The occurrence of new adverse reactions ((ADR)).
|
3 years
|
|
SADR
Time Frame: 3 years
|
The incidence, severity and risk factors of severe adverse reactions ((SADR)).
|
3 years
|
|
Immune-related ADR
Time Frame: 3 years
|
The incidence, severity and risk factors of immune-related adverse reactions.
|
3 years
|
|
The incidence of adverse drug reactions ((ADR)) in special populations.
Time Frame: 3 years
|
3 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
AE
Time Frame: 3 years
|
|
3 years
|
|
SAE
Time Frame: 3 years
|
The incidence of severe adverse events (SAE):
|
3 years
|
|
Immune-related AE.
Time Frame: 3 years
|
The incidence, severity of immune-related adverse events;
|
3 years
|
|
1 -, 2 -, 3-year OS rate.
Time Frame: 3 years
|
Survival indicators: overall survival (OS); 1 -, 2 -, 3-year OS rate.
|
3 years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- JS001-PMS-CO1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.